The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut).
 
Renata Ferrarotto
Consulting or Advisory Role - Ayala Pharmaceuticals; Bicara Therapeutics; Elevar Therapeutics; G1 Therapeutics; Guidepoint Global; Intellisphere; Merck Serono; Prelude Therapeutics; Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); Ayala Pharmaceuticals (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Prelude Therapeutics (Inst)
 
Robert Metcalf
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Cristina P. Rodriguez
Consulting or Advisory Role - Abbvie (I); ADC Therapeutics (I); AstraZeneca (I); beigene (I); Coherus Biosciences; Incyte (I); Karyopharm Therapeutics (I); Kite, a Gilead company (I); Millenium Pharamceuticals (I); Millenium Pharamceuticals (I)
Research Funding - AstraZeneca/MedImmune (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); Denovo Biopharma (Inst); Genentech (Inst); Ignyta (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst)
 
Jameel Muzaffar
No Relationships to Disclose
 
Caroline Even
Consulting or Advisory Role - Bristol-Myers Squibb; Innate Pharma; Merck Serono; MSD Oncology
 
Cesar Augusto Perez
Consulting or Advisory Role - Regeneron
Research Funding - Alkermes (Inst); Artios (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst)
 
Carla M.L.- Van Herpen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Ipsen; MSD
 
Marc Oliva
Honoraria - Merck; MSD Oncology; Transgene
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology
Other Relationship - Bristol-Myers Squibb; Merck; MSD Oncology
 
Bing Xia
Employment - Janssen Research & Development
Honoraria - AstraZeneca
 
Daniel W. Bowles
Consulting or Advisory Role - Blueprint Medicines; Exelixis
 
Aharon Popovtzer
No Relationships to Disclose
 
Eric Winquist
Consulting or Advisory Role - Amgen; Bayer; Eisai; Ipsen; Merck; Roche
Research Funding - Ayala Pharmaceuticals (Inst); Eisai (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Lori J. Wirth
Consulting or Advisory Role - Bayer; Blueprint Medicines; Coherus Biosciences; Eisai; Exelixis; Lilly; Loxo; Merck; Morphic Therapeutic
Research Funding - Ayala Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); CUE Biopharma (Inst); Eisai (Inst); Lilly (Inst)
Expert Testimony - Eisai
Other Relationship - PDS Biotechnology
 
Desiree Hao
Consulting or Advisory Role - Bayer; Bristol Myers Squibb; Bristol Myers Squibb; Novartis Canada Pharmaceuticals Inc; Pfizer; Roche Canada
Research Funding - AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Hyunseok Kang
Honoraria - Axis Medical Education; Cancer Expert Now
Consulting or Advisory Role - Achilles Therapeutics; Bayer; Coherus Biosciences; Exelixis; GlaxoSmithKline; MitoImmune; PIN therapeutics; Prelude Therapeutics; Tempus
Research Funding - Ayala Pharmaceuticals (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Kura Oncology (Inst); Lilly (Inst); NeoImmuneTech (Inst); PDS Biotechnology (Inst); Prelude Therapeutics (Inst)
 
Sebastien J. Hotte
Honoraria - Astellas Scientific and Medical Affairs Inc; Bayer; Eisai; Ipsen; Janssen Oncology; Merck
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SignalChem (Inst)
Travel, Accommodations, Expenses - Eisai
 
Salomon M. Stemmer
Stock and Other Ownership Interests - canfite; CTG Pharma; DocBoxMD; R???'???; tyrnovo; VYPE
Research Funding - AstraZeneca (Inst); BiolineRx (Inst); Bristol-Myers Squibb (Inst); Can-Fite BioPharma (Inst); Clovis Oncology (Inst); CTG Pharma (Inst); Exelixis (Inst); GEICAM (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Moderna Therapeutics (Inst); MSD (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Silenseed (Inst); SynCoreBio (Inst); Taiga (Inst); Teva (Inst); Tiziana Life Sciences (Inst)
Patents, Royalties, Other Intellectual Property - check point inhibitors; combo patent; ctg; vype
 
Ranee Mehra
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Consulting or Advisory Role - Bayer; Rakuten Medical
Research Funding - AstraZeneca; Merck
 
Francis P. Worden
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck Sharp & Dohme; Regeneron
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Loxo; Merck; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Sharp & Dohme
 
Alan Loh Ho
Consulting or Advisory Role - AffyImmune Therapeutics; AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; Cellestia Biotech; CureVac; CureVac; Eisai; Eisai; Exelixis; Genzyme; InxMed; Kura Oncology; McGivney Global Advisors; Merck; Novartis; Prelude Therapeutics; Regeneron; Rgenta; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Ayala Pharmaceuticals; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevar Therapeutics; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Klus Pharma; Kura Oncology; Kura Oncology; Kura Oncology; Merck